Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCO-006
- Development stage
- Preclinical
- Lead developer
- SCOHIA PHARMA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SCO-006 is a first-in-class, orally available small molecule inhibitor of inositol hexakisphosphate kinase (IP6K), specifically targeting the isoforms IP6K1, IP6K2, and IP6K3. Developed by SCOHIA PHARMA, it works by inhibiting the production of inositol pyrophosphates (InsP7), which are key regulators of cellular phosphate export. By modulating these pathways, SCO-006 aims to reduce plasma phosphate levels and improve kidney function, making it a potential treatment for hyperphosphatemia associated with chronic kidney disease. Additionally, it is being investigated for the treatment of ovarian clear cell carcinoma. The compound was previously known as SC-919 in scientific literature and was recognized with the Boehringer Ingelheim Innovation Prize in 2021.
02
Targets
Beyond the preview
Go deeper on SCO-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCO-006.